Posted inBiotechnology
Celldex ends skin disease program after failing phase 2 test
A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech…
Posted inGenetics
UCSD, IGI Partnership Expands CRISPR Innovation Across Health, Agriculture, and the Environment
California may be known as the Golden State, but it may well be referred to as the Genome Editing state…
Posted inBiotechnology
‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraise
A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine…
Posted inBiotechnology
Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge
A group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in…
Posted inGenetics
10x Clinical Expansion Advances with CLIA Lab Plans, Cleveland Clinic Partnership
A researcher at work at Cleveland Clinic’s Pathology and Laboratory Medicine Institute. 10x Genomics is partnering with Cleveland Clinic in…
Posted inGenetics
Blood Cancer Therapies Informed by Spatial Remodeling of Bone Marrow
Cancer cells in blood [wildpixel / iStock / Getty Images Plus] In a new study published in Leukemia titled, “Spatial remodeling of bone…
Posted inBiotechnology
Crystalys mines $130M series B to push gout drug through phase 3
Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and…
Posted inBiotechnology
Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal
For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by…
Posted inGenetics
Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later
Credit: Artemis Diana/Getty Images Revvity reports that its Signals Software business is launching Signals for Startups, a new program designed to…
Posted inBiotechnology
Jupiter enters psychedelics space with $100M deal for PharmAla’s MDMA drug
Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat…